# Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Source: https://onco.cc/trials/nct03351062/  
OnCo record `nct03351062` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tamoxifen and Toremifene in Breast cancer, run by Chinese Anti-Cancer Association, with a status the registry has not verified recently.

## Summary

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer is a phase 3 interventional study registered as NCT03351062 by Chinese Anti-Cancer Association, with 844 participants planned, started 2017-11 and due to reach its primary completion in 2025-12. Interventions recorded: Tamoxifen, Toremifene. Conditions recorded: Breast Cancer Female.

Linked to the drug Toremifene because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03351062
- Phase: 3
- Setting: Multicenter Prospective, Parallel-controlled Phase III Clinical Study on Comparing Efficacy of Tamoxifen Versus Toremifene in CYP2D6 Intermediate/Poor Metabolizers of Premenopausal Patients With ER-positive Early Breast Cancer
- Sponsor: Chinese Anti-Cancer Association
- Enrolled: 844

## Sources

- ClinicalTrials.gov NCT03351062: https://clinicaltrials.gov/study/NCT03351062

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Tamoxifen](https://onco.cc/drugs/tamoxifen/), [Toremifene](https://onco.cc/drugs/toremifene/)

---
JSON: https://onco.cc/api/v1/entities/nct03351062.json